PXD047421 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | Anti-nephrin autoantibodies in minimal change disease and focal segmental glomerulosclerosis (phospho-proteomics) |
Description | Background: Minimal change disease (MCD) and focal-segmental glomerulosclerosis (FSGS) are immune-mediated glomerular diseases manifesting as nephrotic syndrome. Autoantibodies against the podocyte slit diaphragm protein nephrin were recently identified in a subset of patients with minimal change disease, but their clinical and pathophysiological significance is largely unknown. Methods: Using immunoprecipitation assays, we performed a blinded screening for anti-nephrin antibodies in diagnostic and follow-up serum samples from adult patients with biopsy-proven MCD, FSGS, IgA nephropathy, and membranous nephropathy in comparison to healthy controls in two independent patient cohorts from Hamburg, Germany, and Bari, Italy. We further established a mouse model of anti-nephrin antibody-induced disease by active immunization using the recombinant murine nephrin ectodomain. Results: Anti-nephrin autoantibodies were detected in 50 of 110 (45%) patients with MCD, 8 of 107 (7%) patients with FSGS, 1 of 50 (2%) patients with membranous nephropathy, 0 of 48 (0%) patients with IgA nephropathy, and 0 of 67 (0%) healthy individuals. During follow-up, presence, and absence of anti-nephrin autoantibodies in patients with MCD and FSGS strongly correlated with active disease and remission, respectively. Immunization of mice induced anti-nephrin autoantibody formation and a highly dynamic phenotype with severe nephrotic syndrome and the histological features of MCD. Mechanistically, anti-nephrin autoantibodies induced nephrin phosphorylation at Tyr1191, cytoskeletal rearrangement, and downregulation of key podocyte proteins. Conclusion: Anti-nephrin antibodies are a valuable biomarker of disease activity in patients with MCD and FSGS, and binding of anti-nephrin antibodies at the podocyte slit diaphragm induces MCD with nephrotic syndrome. |
HostingRepository | PRIDE |
AnnounceDate | 2024-10-22 |
AnnouncementXML | Submission_2024-10-22_06:42:55.855.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Moritz Lassé |
SpeciesList | scientific name: Mus musculus (Mouse); NCBI TaxID: 10090; |
ModificationList | phosphorylated residue; monohydroxylated residue; iodoacetamide derivatized residue |
Instrument | Orbitrap Exploris 480 |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2023-11-30 14:32:14 | ID requested | |
1 | 2024-05-27 01:12:02 | announced | |
⏵ 2 | 2024-10-22 06:42:56 | announced | 2024-10-22: Updated project metadata. |
Publication List
Keyword List
submitter keyword: focal segmental glomerulosclerosis (FSGS), proteomics, minimal change disease (MCD), autoantibodies, phospho-proteomics,kidney disease, nephrin |
Contact List
Prof. Dr. Markus M. Rinschen |
contact affiliation | III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany |
contact email | m.rinschen@uke.de |
lab head | |
Moritz Lassé |
contact affiliation | Zentrum für Innere Medizin, III. Medizinische Klinik und Poliklinik (Nephrologie/Rheumatologie/Endokrinologie), Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Germany |
contact email | moritz.lasse@gmail.com |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/05/PXD047421 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD047421
- Label: PRIDE project
- Name: Anti-nephrin autoantibodies in minimal change disease and focal segmental glomerulosclerosis (phospho-proteomics)